U.S. markets open in 4 hours 43 minutes
  • S&P Futures

    4,450.00
    -12.50 (-0.28%)
     
  • Dow Futures

    35,093.00
    -78.00 (-0.22%)
     
  • Nasdaq Futures

    15,077.50
    -57.00 (-0.38%)
     
  • Russell 2000 Futures

    2,254.20
    -10.80 (-0.48%)
     
  • Crude Oil

    83.39
    +1.11 (+1.35%)
     
  • Gold

    1,762.20
    -6.10 (-0.34%)
     
  • Silver

    23.33
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1587
    -0.0013 (-0.12%)
     
  • 10-Yr Bond

    1.5760
    +0.0270 (+1.74%)
     
  • Vix

    17.28
    +0.42 (+2.49%)
     
  • GBP/USD

    1.3725
    +0.0048 (+0.35%)
     
  • USD/JPY

    114.3220
    +0.6450 (+0.57%)
     
  • BTC-USD

    61,629.50
    +906.52 (+1.49%)
     
  • CMC Crypto 200

    1,444.84
    +69.62 (+5.06%)
     
  • FTSE 100

    7,222.83
    -11.20 (-0.15%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RED BANK, N.J., Sept. 16, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 22, 2021 at 9:05 am E.T.

(PRNewsfoto/Provention Bio, Inc.)
(PRNewsfoto/Provention Bio, Inc.)

The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contacts:

Robert Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235

Sam Martin, Argot Partners
proventionbio@argotpartners.com
212-600-1902

Media Contact:

Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-and-medtech-summit-301377988.html

SOURCE Provention Bio, Inc.